Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hematopoietic stem cell mobilization | — | D019650 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | — | — | — | 1 |
Plasma cell neoplasms | D054219 | — | — | 1 | 1 | — | — | — | 1 |
Drug common name | Bkt140 |
INN | motixafortide |
Description | Bkt140 is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target C-X-C chemokine receptor type 4. |
Classification | Protein |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3545348 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | DA9G065962 (ChemIDplus, GSRS) |